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Abstract: An ibuprofen-loaded nanostructured lipid carrier (IBU-NLC) was developed for 
enhanced skin penetration to improve the treatment of osteoarthritis and other musculoskeletal 
diseases. The mean particle size was 106 nm, with a spherical morphology, a smooth surface, 
and a zeta potential of -18.4 mV. X-ray diffraction studies revealed the amorphous state of the 
lipid matrix. Both Raman spectroscopy and Fourier transformation infrared analysis indicated 
no major shifts in the spectra of the formulations, which suggest rapid drug dissolution from the 
nanoparticles. The drug loading was 9.85%, and the entrapment efficiency was 98.51%. In vitro 
release of the NLC dispersion, in vitro permeation, and in vivo animal studies of IBU-NLC gel 
all confirmed that the permeation of IBU was significantly better than that of a reference after 
6 hours. In conclusion, IBU-NLC gel is of great potential to enhance drug permeation through 
the skin and hence the efficacy of the treatment of chronic joint inflammation.
Keywords: ibuprofen, nanostructured lipid carriers, skin penetration, SKH-1 hairless mice, 
osteoarthritis
Introduction
Osteoarthritis (OA), one the most prevalent chronic joint diseases, is accompanied by 
considerable pain.1,2 With the current aging of the population and the epidemic of obesity, 
the incidence of OA is rising. The main clinical features, the pain and the loss of function, 
lead to treatment by nonpharmacological, pharmacological, and surgical approaches.1 
In a study involving 3,906 patients above the age of 55 years, 67% of the women and 
54.8% of the men suffered from radiographic OA in at least one hand joint.1,3 Another 
study confirmed that some 40% of the total population aged .70 years suffer from OA, 
the most common form of arthritis.2,4 Since pain and inflammation are among the most 
important causes of a decline in the life quality, the primary aim of the currently available 
treatments is to relieve these. The American College of Rheumatology has published 
recommendations for the use of nonpharmacologic and pharmacologic therapy in OA. 
The use of nonsteroidal anti-inflammatory drugs is highly recommended.5
Ibuprofen (IBU) is a nonsteroidal anti-inflammatory drug that was introduced 
in the 1960s to replace acetylsalicylic acid in the treatment of rheumatoid arthritis, 
providing a more efficacious therapy and proving more tolerable for the patients. It 
is administered orally or topically in the form of gels, creams, and ointments. The 
advantages of its local application over their systemic use include the avoidance of 
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adverse events (bleeding and possible ulceration of the gastric 
mucosa) and the high concentration of the drug at the site 
where it is needed. The drug, usually administered in its 
racemic form,6 is relatively lipophilic (log P=4.0) with low 
water solubility (21 mg/L at 25°C).6,7 The characteristics of 
the permeation of IBU through the human skin have been 
reported by a number of research groups.8–13 Earlier studies 
revealed that the topical therapeutic effectiveness of a drug 
is a function both of its penetration through the skin and of 
its potency.7 IBU is less potent than diclofenac, for example, 
but the higher flux of IBU through the skin means that it is 
a better candidate for topical delivery, although it is still 
difficult to achieve its effective permeation by transdermal 
delivery.14 The aforementioned physicochemical properties 
of IBU have hampered the preparation of a formulation 
satisfying the requirements of a long-lasting treatment for a 
chronic disease such as OA.
Nanostructured lipid carriers (NLCs) may serve as a 
solution to overcome the limitations of the dermal permeation 
of IBU. This drug delivery system offers numerous advantages 
for topical application.15–19 NLCs can comprise physiological 
and biodegradable lipids, which were earlier reported to pos-
sess low systemic toxicity and low cytotoxicity.20 The small 
size of the lipid nanoparticles ensures close contact between 
the lipid particles and the lipid bilayer of the stratum corneum, 
resulting in the penetration of an increased amount of drug into 
the skin. In consequence of their solid lipid matrix, controlled 
release is possible from these carriers. This becomes impor-
tant when prolonged release of the drug is required. Burst 
release of the drug incorporated in the NLC system may also 
be achieved.21 As a result of the film formation that occurs 
after topical application, occlusive properties have also been 
reported for NLC formulations,22,23 and these favor further 
enhanced penetration through the dermal layers.
The aim of the present study was to develop a hydrogel 
based on an IBU-loaded NLC (IBU-NLC) system, with 
improved drug release properties (for the potential treatment of 
OA or musculoskeletal disorders) as compared with those of a 
traditional IBU gel formulation and to characterize this hydro-
gel by means of techniques such as X-ray diffraction (XRD), 
atomic force microscopy (AFM), Raman spectroscopy, and 
Fourier transformation infrared (FT-IR) spectroscopy in order 
to attain a better understanding of its properties.
Materials and methods
Materials
IBU was provided by PannonPharma Ltd. (Pécsvárad, 
Hungary), Witepsol E85 and Miglyol 812 were gifts by Sasol 
GmbH (Hamburg, Germany), and Lutrol F68 was kindly 
supplied by BASF SE Chemtrade GmbH (Ludwigshafen, 
Germany). Acetonitrile (high-performance liquid chroma-
tography [HPLC] grade), K
2
HPO
4
, KH
2
PO
4
, and H
3
PO
4
 
(85%) (analytical grade) were purchased from VWR Int Ltd 
(Radnor, PA, USA). Carbopol 971P NF was supplied by 
Azelis Ltd (Budapest, Hungary). Macrogol 400 was obtained 
from Hungaropharma Ltd (Budapest, Hungary). Purified 
water (HPLC grade) produced with a TKA Smart2Pure 
system (TKA GmbH, Niederelbert, Germany) was used to 
prepare all the formulations.
Preparation of the samples
The NLC formulations were prepared by a hot high-pressure 
homogenization method,17,18,24,25 using an Emulsiflex C-3 
High Pressure Homogenizer (Avestin Europe GmbH, 
Mannheim, Germany). Briefly, 1% IBU was dissolved in 
the mixture of the solid and liquid lipids (Witepsol E85 and 
Miglyol 812, ratio 7:3) at ~10°C above the melting point of 
the solid lipid. The surfactant, Lutrol F68, was dissolved in 
purified water at the same temperature. The aqueous phase 
was added to the lipid phase, and the mixture was stirred with 
a Heidolph DIAX 900 homogenizer (Heidolph Instruments 
GmbH & Co. KG, Schwabach, Germany) for 1 minute at 
12,500 rpm. The pre-emulsion was subjected to high-pressure 
homogenization, applying five cycles at 600 bar and 65°C. 
The hot oil-in-water pre-emulsion was cooled in an ice bath 
to recrystallize the lipid and form the NLC.
An IBU suspension containing 1% of IBU dispersed 
in purified water was prepared as a reference for in vitro 
diffusion studies of IBU-NLC. For the in vitro penetration 
and in vivo permeation studies, IBU-NLC was gelled with a 
previously prepared 3% Carbopol 971P NF gel in a ratio of 
1:1. For comparison, 0.5% IBU was dissolved in Macrogol 
400 and gelled with the same polymer.
Particle size characterization and zeta 
potential measurements
The particle sizes of the prepared blank NLC and IBU-NLC 
formulations were analyzed by photon correlation spec-
troscopy (PCS) (Zetasizer Nano ZS; Malvern Instruments, 
Malvern, UK). The presence of particles in the micrometer 
range was excluded by laser diffraction (LD) (Mastersizer 
2000; Malvern Instruments). The diameters of 10%, 50%, 
and 90% (d(0.1), d(0.5), and d(0.9)) of the particles were 
evaluated. The medium was purified water.
To obtain information concerning the stabilities of the 
prepared samples, their zeta potentials were determined with 
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a Zetasizer Nano ZS (Malvern Instruments). The medium 
was double-distilled water.
atomic force microscopy
The particle size of the blank and IBU-NLC samples was 
also determined by AFM for comparison with the results 
obtained by PCS and LD measurements. The tapping 
mode was used on a SOLVER Scanning Probe Microscope 
(NT-MDT Co, Moscow, Russia) under ambient conditions. 
PPP-NVHAuD-10 (NANOSENSORS™; NanoWorld AG, 
Neuchatel, Switzerland) AFM tips with a nominal radius of 
curvature of 2 nm and a length of 15 µm were used.
XrD analysis
Diffractograms of the raw materials (IBU, Witepsol E85, and 
Lutrol F68), the melted physical mixtures of the raw materi-
als with or without IBU, and the blank NLC and IBU-NLC 
were obtained with a Bruker D8 Advance diffractometer 
(Bruker AXS GmbH, Billerica, MA, USA) system with Cu 
K λI radiation (λ =1.5406 Å). Each sample was scanned at 
40 kV and 40 mA in the interval 3°–40° 2θ, at a scanning 
speed of 0.1/second and a step size of 0.010°.
DXr raman spectroscopy measurements
IBU, Witepsol E85, Miglyol 812, and Lutrol F68 (as standard 
components of the NLC), blank, and IBU-NLC samples were 
characterized. Raman spectra were recorded with a Thermo 
Fisher DXR Dispersive Raman spectrometer (Thermo Fisher 
Scientific Inc., Waltham, MA, USA) attached to an Olympus 
MPlan ×10/0.25 BD microscope (Olympus Corporation, 
Tokyo, Japan). At least five measurements were made 
at 532 nm with the in-built fluorescence and cosmic ray 
correction to ensure low background noise. Measurement 
conditions were as follows: power on the surface of the 
sample, 3 mW; diameter spot (×10 magnification objective), 
3 µm; and aperture of the pinhole with 50 µm. Samples were 
packed onto an aluminum sample holder, and spectra were 
collected for a total of 48 scans at a spectral resolution of 
4 cm–1. For the characterization of IBU and NLC samples, 
the full spectral range (3,000–200 cm-1) was used. IBU-NLC 
and blank NLC compositions were investigated by Raman 
mapping to localize the IBU inside the formulation. To 
identify the individual components in the Raman spectra, the 
vibrational chemical images were processed by a multivari-
ate curve resolution – alternating least squares chemometric 
method. The NLC compositions were dried overnight on 
the aluminum surface to stabilize the NLC droplets for the 
Raman analysis. The 200–220 µm ×60 µm flat surfaces were 
analyzed at a step size of 10 µm. The acquisition time was 
3 seconds per spectrum. Twenty-four spectra were accu-
mulated and averaged at each measured point, ensuring an 
acceptable signal-to-noise ratio. The Raman spectra were 
then normalized to eliminate the intensity deviation between 
the measured areas.
FT-Ir spectroscopy
FT-IR measurements of the pure drug and the NLC dispersions 
(blank and IBU-NLC) were performed with a Bio-Rad Digilab 
Division FTS-65A/896 FTIR spectrometer (Bio-Rad Labo-
ratories Inc., Hercules, CA, USA) in the wavelength range 
4,000–400 cm-1, 128 scan size, and at an optical resolution 
of 4 cm-1. The operating conditions were Harrick’s Meridian 
SplitPea single reflection, diamond, and attenuated total reflec-
tance accessory. The spectrum of the drug-loaded composition 
was processed to deconvolution in the range 1,800–1,660 cm-1 
by a curve-fitting algorithm with a Gaussian–Lorentzian func-
tion. The best curve-fitting procedure was performed by itera-
tive fits toward a minimum standard error. Thermo Scientific 
GRAMS/AI Suite software (Thermo Fisher Scientific Inc.) 
was used for the spectral analysis.
Drug loading and entrapment efficiency 
measurements
Drug loading (DL%) and entrapment efficiency (EE%) were 
evaluated by an indirect method, with measurement of the 
free drug concentration in the external aqueous phase:26,27
 
DL% initial drug free drug
lipid
=
−
%
W W
W
×100  (1)
 
EE% initial drug free drug
initial drug
=
−
%
W W
W
×100  (2)
where W is the weight in milligrams.
One hundred microliters of the IBU-NLC sample and 
400 µL of phosphate-buffered saline (PBS) were transferred 
into a Nanosep 3K ultrafilter Eppendorf tube having an 
molecular weight cut-off of 3 kDa (Pall Co, Port Washington, 
NY, USA) and centrifuged at 5,055 rpm for 10 minutes. The 
solution obtained was filtered through a 0.20 µm polyether-
sulfone syringe membrane filter and injected directly into 
the HPLC system.
The IBU content was quantified with an Agilent 1260 HPLC 
system (chimically pure [QP], diode array detector, alternat-
ing least squares). IBU was measured on a 100 mm ×4.6 mm 
International Journal of Nanomedicine 2016:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1204
Sütő et al
column packed with 3 µm Luna C18, 100 Å (Phenomenex 
Inc., Torrance, CA, USA). Isocratic elution was performed 
with 40:60 (v/v) MeCN-PBS (0.025 M) (pH adjusted to 
2.7 with orthophosphoric acid) at a flow rate of 1 mL/min. 
The buffer was prepared from KH
2
PO
4
 and K
2
HPO
4
. Before 
use, the eluent was degassed. The run time was 10 minutes. 
Detection was performed via the absorption at 215±4 nm. 
Ten microliters of sample was injected, and the elution was 
carried out at a sample temperature of 27°C and a column 
temperature of 35°C. Qualitative determination was achieved 
by comparison with the spectra of standards. The stock solu-
tion of IBU (0.5 mg/mL) was prepared in methanol and stored 
at 4°C. Working standards (1, 5, 10, 25, 50, and 100 µg/mL) 
were prepared freshly by diluting the stock solution with the 
mobile phase prior to the HPLC analysis. Calibration plots 
were freshly prepared and were highly linear (R2.0.9998) in 
the concentration range 1.0–100.0 µg/mL (n=3–4).
In vitro release, in vitro permeation, and 
in vivo animal studies
The in vitro drug release study was carried out by using the 
dialysis bag method.24,28,29 Briefly, 200 µL of the IBU-NLC 
formulation was sealed in a Spectra/Por® 4 dialysis mem-
brane (Spectrum Laboratories, Inc., Rancho Dominguez, CA, 
USA), with Spectra/Por® Closures (Spectrum Laboratories, 
Inc.), and placed into 25 mL of PBS (pH 7.4). The system 
was held at 37°C to mimic in vivo conditions and continu-
ously stirred at 450 rpm. At selected time intervals during 
6 hours, 1 mL of bulk solution was taken. The withdrawn 
samples were each replaced by 1 mL of PBS to maintain sink 
conditions. Blank NLC served as blank and was analyzed in 
the same way as IBU-NLC. A previously prepared 1% IBU 
suspension was subjected to the same procedure, to serve 
as a reference.
The ex vivo permeation studies were performed with a ver-
tical Franz diffusion cell system (Hanson Microette TM Topi-
cal & Transdermal Diffusion Cell System; Hanson Research 
Corporation, Chatsworth, CA, USA). A 0.300–0.400 g 
of 0.5% IBU-NLC gel or 0.5% IBU gel (which served as 
a reference) was measured as donor phase on pretreated 
excised human skin10,30 supported by a Porafil® CM mem-
brane (pore diameter 0.45 µm; Macherey-Nagel GmbH & 
Co. KG, Düren, Germany). The effective diffusion surface 
area was 1.3 cm2. PBS (pH 7.4) was used as acceptor phase. 
The rotation of the magnetic stirbar was set to 450 rpm. The 
receptor medium was thermostated at 37°C±0.5°C to ensure 
the physiological skin temperature, 32°C at the site of the 
sampling. Experiments were performed for 6 hours. Samples 
of 0.8 mL were taken from the acceptor phase at given 
times by the autosampler (Hanson Microette Autosampling 
System; Hanson Research Corporation) and replaced with 
fresh receiving medium.
The samples from both experiments were analyzed at 
263 nm with a Unicam Evolution 201 UV/Vis spectropho-
tometer (Thermo Fisher Scientific Inc.).
The in vivo animal studies were performed on 11- to 
13-week-old male SKH-1 hairless mice (body weight: 
28–34 g). The procedures and protocols applied were approved 
by the Ethical Committee for the Protection of Animals in 
Scientific Research at the University of Szeged (license num-
ber: V./145/2013) and the Ethical Committee of the Human 
Investigation Review Board at Albert Szent-Györgyi Clinical 
Centre, University of Szeged, 83/2008. The modified dorsal 
skin fold chamber was used to determine IBU penetration 
through living animal skin by a previously described meth-
od.31 This experimental setup provides an effective means of 
performing in vivo examinations of permeation.
The mice were randomly allocated into the following 
groups. The animals in group 1 (n=5) received IBU gel. 
In group 2 (n=7), IBU-NLC gel was used. 0.1 g of the study 
formulation was applied to the skin. One milliliter of PBS 
(pH 7.37) was added as the chamber acceptor phase. The 
observation period lasted for 6 hours. At given time points, 
the PBS was replaced by fresh PBS. The concentration of the 
penetrated drug was measured by means of HPLC. Previous 
tests of the blank NLC gel indicated that the components of 
this gel do not interfere with HPLC detection of the active 
agent. At the end of the experiment, the animals were eutha-
nized with an overdose of ketamine.
The HPLC instrumentation included a Shimadzu CBM-
20A/20Alite system controller, a Shimadzu LC-20AD solvent 
delivery system, a Shimadzu DGU-20A3 on-line degasser, a 
Shimadzu SPD-M20A UV/VIS photodiode array detector, 
and a Shimadzu CTO-20A column oven (Shimadzu Corp, 
Kyoto, Japan). The chromatographic system was equipped 
with a Rheodyne Model 7725i injector (IDEX Corp, Lake 
Forest, IL, USA) with a 20 µL loop. The chromatographic 
data were collected and processed by means of Shimadzu 
LCsolution software (Shimadzu Corp).
statistical analysis
The results were evaluated and analyzed statistically with 
the two-way analysis of variance test (Bonferroni’s multiple 
comparison), using Prism for Windows 5 software (GraphPad 
Software Inc., La Jolla, CA, USA). The data are the averages 
of the results of at least five experiments ± standard deviation 
(*P,0.05, **P,0.01, ***P,0.001, and ****P,0.0001 
versus the control).
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Results
results of particle size and zeta potential 
measurements
Particle size determination by PCS demonstrated that both 
samples were in the nanometer range, with an effective 
particle size (Z
ave
) of 114 nm for the blank NLC and 106 nm 
for IBU-NLC. LD measurements confirmed that larger 
particles (.1 µm) were not present in the formulations, and 
90% of the particles measured ,205 nm. The surface charge 
was negative for both the blank (-15.9 mV) and IBU-NLC 
(-18.4 mV) (Table 1).
results of aFM measurements
Both samples were measured by AFM to confirm the PCS and 
LD results. The data were evaluated by grain analysis, and 
size distribution histograms were made (Figure 1A and B). 
The Z values of most of the blank NLC particles were 
between 109 and 124 nm, while those of the IBU-NLC were 
between 95 and 118 nm (Figure 1C and D), verifying the 
PCS and LD results.
AFM has been widely used to acquire information on 
the size, shape, and surface morphology of nanoparticles.32 
In all the present samples, the separated lipid particles were 
spherical or nearly spherical with a smooth surface (Figure 2). 
No major differences were detected between the blank and 
IBU-NLC samples, although some larger lipid agglomerates 
were found in the IBU-NLC. This is probably due to the 
sample preparation process: the pretreatment (sonication) 
was unable to disperse the previously dried lipid particles 
completely.
results of XrD
XRD measurements were carried out to determine the possible 
changes in the crystallinity of the components during the hot 
high-pressure homogenization procedure. Diffractograms 
of the pure, untreated components (IBU, Witepsol E85, and 
Lutrol F68) are depicted in Figure 3. Diffractograms were 
also recorded of the melted lipid mixture (Witepsol E85 and 
Miglyol 812 in a ratio of 7:3) with or without IBU, the melted 
total physical mixture, the blank, and IBU-NLC. The crystal-
linity of the solid lipid (plot 2) decreased to such an extent 
after the addition of the excipients (plots 4 and 6) and the drug 
(plot 5) that the material became amorphous in the cases of the 
prepared blank (plot 7) and IBU-NLC (plot 8) formulations. 
This suggests that both of the NLC formulations have a struc-
tureless solid amorphous matrix and belong to the amorphous 
NLC type.33 The XRD pattern of pure racemic IBU (plot 1) 
exhibited characteristic diffraction peaks at various diffraction 
angles (6°, 12.3°, 16°, 20.4°, and 22.3° 2θ), indicating the 
presence of crystallinity.34 These peaks also appeared in the 
plot of the melted mixture of the lipid matrix and the active 
pharmaceutical ingredient (plot 5) but were absent from those 
of the total mixture (plot 6) IBU-NLC (plot 8).
results of DXr raman spectroscopy 
measurements
Raman spectroscopy was employed to confirm the physical 
state of the IBU and to study the possible physicochemical 
interactions between the components. The Raman spec-
tra of dried free racemic IBU, Lutrol F68, Witepsol E85, 
and Miglyol 812 are presented in the wavenumber range 
2,000–200 cm-1 in Figure 4A. As model solutions, IBU was 
dissolved in Miglyol 812 in two concentrations (10% and 
25%, w/w), to observe the principal differences in the physi-
cal state of the IBU (Figure 4B). The spectra of IBU, the blank 
NLC, and IBU-NLC are presented in Figure 4C.
The selected Raman bands of IBU, the IBU-containing 
Miglyol model solutions, and the IBU-NLC composition with 
the vibrational assignments (cm-1) are presented in Table 2. 
The chemical structure of Miglyol is very similar to those 
of the other lipid components, and therefore, the bands from 
the IBU-NLC sample, Raman spectrum characteristic of 
Miglyol 812, could be overlapped by the bands characteristic 
of other lipids.
The IBU spectrum exhibited characteristic peaks at 1,608, 
1,576, 1,208, 1,182, 1,008, 959, 834, 746, 638, and 415 cm-1. 
These peaks are attributed mainly to aryl ring stretching and 
C
24
-Ar-C
11
 conformational stretching and wagging. Medium 
sharp peaks are attributed to Ar and Ar-CH in-plane and 
out-of-plane bending. In spite of the many free racemic 
IBU peaks, the Raman spectra of the model solutions and 
the NLC composition were characteristic of the auxiliary 
Table 1 Particle size, zeta potential, polydispersity index, span value, and average Z (height) value of the blank Nlc and IBU-Nlc 
formulations (the measurements were performed in triplicate, n=3)
Sample Zave (nm) ZP (mV) PDI d(0.1) (nm) d(0.5) (nm) d(0.9) (nm) Span value Average Z (nm)
Blank Nlc 114±2.2 -15.9±0.7 0.15±0.1 67±0 118±0 204±0.6 1.16±0 113.67±15.5
IBU-Nlc 106±1.7 -18.4±1.3 0.18±0.3 74±0 122±0 205±0.6 1.07±0 107.47±14.4
Abbreviations: Nlc, nanostructured lipid carrier; IBU-Nlc, ibuprofen-loaded nanostructured lipid carrier; ZP, zeta potential; PDI, polydispersity index; Zave, effective 
particle size.
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Figure 1 Z value distribution (height) of blank Nlc (A) and IBU-Nlc (B) and Z value (height) of blank Nlc (C) and IBU-Nlc (D) (n=3).
Abbreviations: Nlc, nanostructured lipid carrier; IBU-Nlc, ibuprofen-loaded nanostructured lipid carrier.
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Figure 2 2D images of blank Nlc (A) and IBU-Nlc (C). 3D images of blank Nlc (B) and IBU-Nlc (D) revealing the morphology and size of the formulations (n=3).
Abbreviations: 2D, two dimensional; Nlc, nanostructured lipid carrier; IBU-Nlc, ibuprofen-loaded nanostructured lipid carrier; 3D, three dimensional.
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Figure 4 raman spectra of (A) individual components, (B) model solutions, and (C) Nlc compositions.
Notes: (A) IBU (1), lutrol F68 (2), Witepsol e85 (3), and Miglyol 812 (4); (B) IBU (1) model solutions of 10% IBU (2), 25% IBU (3), Miglyol 812 (4); (C) IBU (1), blank Nlc 
(2), IBU-Nlc (3).
Abbreviations: IBU, ibuprofen; Nlc, nanostructured lipid carrier; IBU-Nlc, ibuprofen-loaded nanostructured lipid carrier.
materials. The medium-intensity IBU peaks at 1,452, 1,341, 
1,116, 943, 820, 662, 784, and 269 cm-1 (C
x
–H
y
 bending, 
twisting, or rocking) were absent from the spectra of the 
IBU-containing model solutions and NLC composition. 
Comparison of the Raman peaks of the IBU and the model 
solutions (10% and 25%) revealed small shifts in the 
wavenumbers of the characteristic IBU peaks. Moreover, 
the Raman spectrum of the IBU-NLC composition (with 
less characteristic IBU peaks) revealed the same small shifts, 
indicating the occurrence of weak interactions between 
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Table 2 Observed raman peaks (in cm-1) and peak assignments of free racemic IBU and IBU-containing model solutions and Nlc 
compositions
IBU (literature) Assignment 10% 25% IBU-NLC
1,608 s(c–c)ar 1,613 1,609 1,616
1,576 s(c–c)ar and v(c=c)ar 1,574 1,574 –
1,208 t(ch2) (c11–c12–c13) 1,207 1,206 1,208
1,182 s(c6–c11) 1,185 1,182 1,185
1,008 in(ch)ar 1,004 1,007 1,004
959 r(c26h3) and antisymmetric s(c26–c24–c30) 957 957 955
834 out(ch)ar 832 833 –
746 r(ch3) and out(ch)ar 739 745 –
638 out(cO–h) and in(ar) 637 636 –
415 d(c15–c14–c19) 405 412 –
Notes: assignments have been compared with those found in the literature in order to seek for peak shifts (n=3). Significant shifts appear in bold.
Abbreviations: IBU, ibuprofen; Nlc, nanostructured lipid carrier; IBU-Nlc, ibuprofen-loaded nanostructured lipid carrier; s, stretching; ar, aromatic; v, vibration; 
t, twisting; in, in-plane bending; r, rocking; out, out-of-plane bending; d, deformation.
Table 3 Observed raman peaks (in cm-1) and peak assignments of individual lipid components and Nlc compositions (n=3)
Assignment Lutrol F68 Witepsol E85 Miglyol 812 Blank NLC IBU-NLC
s(ch) 2,934 2,935 2,931 2,936 2,935
s(ch2) antisymmetric 2,884 2,880 – 2,881 2,881
s(ch2) symmetric – 2,846 2,853 2,850 2,850
s(ch) – 2,724 2,728 2,724 2,725
s(c=O) – 1,739 1,745 1,741 1,742
ch2 scissoring and s(c–O) – 1,438 1,439 1,441 1,441
t(ch2) and s(c–O) – 1,295 1,302 1,297 1,297
s(c–c) symmetric and s(c–O–c) asymmetric 1,125 1,126 – 1,128 1,128
s(c–c) asymmetric and s(c–O) symmetric 1,062 1,062 1,063 1,063 1,063
r(ch3) – 889 889 889 892
r(ch3) 843 – 841 844 845
Abbreviations: Nlc, nanostructured lipid carrier; IBU-Nlc, ibuprofen-loaded nanostructured lipid carrier; s, stretching; t, twisting; r, rocking.
IBU and the lipids. A significant change in the spectrum 
of interacted IBU was the shift in the peak corresponding 
to the aryl C–C stretching from 1,608 to 1,609–1,616 cm-1. 
This latter shift indicates that the aryl ring is affected by the 
interaction with the lipid molecules and not the C=O group 
of IBU. In Table 3, the Raman spectra of the lipid compo-
nents are compared with those of IBU-NLC and the blank 
NLC. The lipid components used in this study have similar 
chemical structures and therefore similar Raman bands. 
The Raman spectra of the lipid components in the range 
3,000–200 cm-1 displayed characteristic peaks, which are 
assigned to vibrations of the fatty acid hydrocarbon chains. 
The sharp and intense peaks at 2,881 and 2,850 cm-1 and 
the medium peaks at 1,128 and 1,062 cm-1 in all the NLC 
compositions confirmed the ordered acyl chains in the lipid 
structure. The incorporation of IBU did not lead to the disap-
pearance of the sharp bands at 2,881 and 2,850 cm-1 in the 
Raman spectrum of IBU-NLC.
In order to confirm the homogeneity of the IBU, Raman 
mapping of the NLC was performed. Figure 5A shows 
the distribution map of IBU in the NLC composition 
at ×10 magnification. The characteristic bands obtained for 
IBU at ~1,608 cm-1 were used to visualize the spatial distri-
bution of IBU from Raman chemical mapping. The IBU was 
found homogeneously in the dried, round areas. The purpose 
of this analysis was to estimate the distribution of the indi-
vidual ingredients in the scanned area. The spectra of the 
estimated “Components” were compared with the reference 
ingredient spectra (Figure 5B). The spectra of components 
1 and 4 were identified as the Raman spectrum of Lutrol 
F68, with characteristic Raman band regions of 1,750–1150, 
900–750, and 400–200 cm-1. The resolved spectrum of 
component 2 does not correspond to the reference spectra 
but contains similar Raman bands to those of Miglyol 812. 
The spectrum of component 2 displays several other peaks; 
the reason may be the low signal-to-noise ratio. Component 3 
corresponds to Witepsol E85, with very characteristic Raman 
band regions of 1,500–1,400 and 1,150–1,000 cm-1. The 
Raman spectra of each component contain the characteristic 
Raman peaks of IBU at 1,614–1,608 cm-1.
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Figure 5 (A) raman distribution map of IBU in the IBU-Nlc composition (×10 magnification). (B) Multivariate curve resolution of IBU-Nlc raman chemical mapping. 
spectra of the estimated ingredients, “components”, are compared to reference spectra of individual ingredients (n=3).
Note: The box highlights the small peaks/shoulders, which are characteristic to the drug, and a significant shift has occurred in their position compared to the native spectrum 
of ibuprofen.
Abbreviations: IBU, ibuprofen; IBU-Nlc, ibuprofen-loaded nanostructured lipid carrier; comp, component.
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Figure 6 (A) FT-Ir spectra of IBU-Nlc, blank Nlc, and IBU. (B) Deconvolution of IBU-Nlc from 1,800 to 1,665 cm-1 (n=3). 
Abbreviations: FT-Ir, Fourier transformation infrared; IBU-Nlc, ibuprofen-loaded nanostructured lipid carrier; Nlc, nanostructured lipid carrier; IBU, ibuprofen.
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results of FT-Ir
The FT-IR spectra of the excipients, blank NLC, and IBU-
NLC were recorded to obtain information about the possible 
interactions between IBU and the matrix of the nanoparticles. 
Analysis of the spectrum of IBU-NLC clearly indicates that 
there are no strong interactions between the drug and the 
excipients (Figure 6A). Comparison of the FT-IR spectra of 
the blank NLC and the drug-loaded IBU-NLC at 1,700 and 
1,550 cm-1 revealed two peaks (which are characteristic of the 
drug) as shoulders in the spectrum of IBU-NLC (Figure 6A, 
marked peaks). After the deconvolution of the wavelength 
range 1,800–1,660 cm-1, the characteristic peak of IBU at 
1,721 cm-1, described as the vibration of the C=O bond,35 
could be characterized (Figure 6B). The boxes in Figure 6 
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highlight the small peaks/shoulders, which are characteris-
tic to the drug, and a significant shift has occurred in their 
position compared to the native spectrum of ibuprofen. The 
intensity of this peak is low, which means that nondissolved 
IBU is present in low concentrations. The presence of drug 
crystals could be due to the pretreatment of the samples before 
the measurement (the NLC dispersions were dried in air).
results of drug loading and entrapment 
efficiency
From the results of the applied HPLC method, DL was found 
to be 9.85%±4.10% and EE 98.51%±4.10% for the prepared 
IBU-NLC composition, since 1.49%±4.10% of the IBU was 
measured in the outer aqueous phase.
results of in vitro release, ex vivo 
permeation, and in vivo animal studies
The in vitro diffusion of IBU through the artificial membrane 
from IBU-NLC and the IBU suspension was calculated 
in terms of the mean cumulative amount diffused at each 
sampling time point during a period of 6 hours (Figure 7A). 
The amount of IBU diffused from the IBU-NLC after 6 hours 
was significantly higher (2.59-fold) than that from the IBU 
suspension.
The ex vivo penetration of the drug from the prepared 
IBU-NLC gel and IBU gel through excised human skin was 
calculated in the same way as for the in vitro measurements 
(Figure 7B). The permeation of IBU through the excised 
human skin was 12.78-fold higher from the IBU-NLC gel 
than from the traditional IBU gel. These findings correlate 
with those of the in vitro diffusion study, since after 6 hours, 
much higher drug permeation could be observed from the 
IBU-NLC gel than from the IBU gel.
Finally, the in vivo permeation of IBU from the IBU-NLC 
gel and the IBU gel was determined with a murine model, 
using a modified dorsal skin chamber; the results are 
presented in Figure 7C. The drug penetration was signifi-
cantly higher (1.87-fold, P.0.001) from the IBU-NLC gel 
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Figure 7  In vitro (A), ex vivo (B), and in vivo (C) studies of IBU-Nlc gel.
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Abbreviations: IBU, ibuprofen; IBU-Nlc, ibuprofen-loaded nanostructured lipid carrier; h, hours.
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formulation than from the IBU gel, as found in the previous 
in vitro and ex vivo studies.
Discussion
An NLC-based gel of IBU was produced. Characterization of 
the IBU-NLC dispersion by PCS, LD, and AFM proved the 
appropriate size range and morphological properties of the 
lipid nanoparticles, which are essential for the stability and the 
desired performance of the formulation. XRD measurements 
and the high EE (98.51%) both confirmed the presence of 
IBU as a molecular dispersion in the lipid matrix of the final 
formulation. The results of Raman spectroscopy and FT-IR 
analysis indicated that the ordered lipid structure was not 
affected by the presence of the IBU molecules. The homoge-
neous distribution of the IBU in the lipid matrix and the weak 
interactions between the drug and the excipients predicted 
rapid drug liberation, since there is no need for energy to 
break the bonds between the drug and the excipients. These 
findings were confirmed by drug diffusion and permeation 
studies. The in vitro diffusion study demonstrated higher drug 
permeation from the IBU-NLC than from the IBU suspension. 
The permeation of IBU through the excised human skin was 
also significantly higher from the IBU-NLC gel than from the 
IBU gel. The higher penetration rate is probably due to the 
direct contact between the lipid nanoparticles and the lipids 
of the stratum corneum, which results in the increase of the 
penetration channels through the skin. The NLC carrier-based 
gel facilitated the drug permeation through the living animal 
skin even under physiological conditions.
It can be concluded that the IBU-NLC gel is of great 
potential to increase drug permeation through the skin and 
enhance the efficacy of the treatment for OA and other mus-
culoskeletal inflammations.
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